Reuters logo
BRIEF-RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE
October 3, 2017 / 4:05 PM / in 18 days

BRIEF-RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc:

* RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE

* PROCEEDS WILL ALLOW CO TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE

* ‍PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE EXPECTED TO BEGIN IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below